Simplified Chinese
scroll down
03
2025-01
From mumps to deafness, what caused him lifelong regret?
A few days ago, a deaf-mute elderly man living near our community passed away. It is said that in his childhood he was bright and quick-witted, but a bout of mumps left him quiet and withdrawn, eventually rendering him deaf and mute. Because of this, he spent his entire life in a world without sound, rarely interacting with those around him, and ultimately died alone. His passing has left many people shaking their heads in sorrow. Now let’s talk about the potency of mumps and how to prevent it through vaccination. Do you remember the “mumps” you had as a child? While the term may sound unfamiliar today, back in the 1960s it was a common infectious disease—often seen as one or both sides of the cheeks swelling up, vividly…
18
2024-11
On November 16, the inaugural China Pharmaceutical Valley Future Biologics Innovative Drug Conference was successfully held at the Kapok Hotel in Daxing District. Hosted by the Management Committee of the Daxing Biopharmaceutical Industry Base of Zhongguancun Science Park and co-organized by six entities—including Beijing Hotgen Biotechnology Co., Ltd. and Beijing Minhai Biotechnology Co., Ltd.—the event brought together numerous academicians, industry experts, and leading entrepreneurs to discuss cutting-edge industry trends, foster deep integration of key factors driving the pharmaceutical and healthcare sectors, and further enhance Daxing District’s influence in the field of innovative drugs. Zheng Haifa, Chief Scientist of Kintor Pharmaceutical and General Manager of Minhai Biotechnology, was invited to attend the conference.
14
2024-10
In accordance with the “Decision of the State Council on Amending the Regulations on Environmental Protection Management of Construction Projects” (State Council Order No. 682) and the “Notice on the Issuance of the Interim Measures for Environmental Protection Acceptance upon Completion of Construction Projects” (Guohuan Gui Huanping [2017] No. 4), the “Environmental Protection Acceptance Report upon Completion (Phase I) for the Minhai Biotechnology International Vaccine Industrial Base Project” is hereby made public as follows: Project Name: Construction of the Minhai Biotechnology International Vaccine Industrial Base (Phase I) Project Undertaker: Beijing Minhai Biotechnology Co., Ltd. Publicized Contents: The environmental protection acceptance report upon completion, along with any other matters requiring clarification.
14
2024-10
In accordance with the “Decision of the State Council on Amending the Regulations on Environmental Protection Management of Construction Projects” (State Council Order No. 682) and the “Notice on the Issuance of the Interim Measures for Environmental Protection Acceptance upon Completion of Construction Projects” (Guohuan Gui Huanping [2017] No. 4), the “Environmental Protection Acceptance Report upon Completion (Phase I) for the Minhai Biotechnology International Vaccine Industrial Base Project” is hereby made public as follows: Project Name: Construction of the Minhai Biotechnology International Vaccine Industrial Base (Phase I) Project Undertaker: Beijing Minhai Biotechnology Co., Ltd. Publicized Contents: The environmental protection acceptance report upon completion, along with any other matters requiring clarification.
29
2024-09
In accordance with the Measures for Public Participation in Environmental Impact Assessment (Order No. 4 of the Ministry of Ecology and Environment), before submitting the environmental impact assessment documents to the competent environmental protection authority for approval, the project proponent shall publicly disclose the full text of the environmental impact report and the public participation statement. The Environmental Impact Report for the Nucleic Acid Vaccine R&D and Pilot-Scale Production Project, together with the public participation statement, is hereby made public. This project does not contain any information that, by law, should remain confidential; therefore, the disclosed version comprises the complete report. To access the public participation statement, please use the following link: https://pan.baidu.com/s/1dT1iSCN6bnA_MgRWd945GA.
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%